HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reauthorization Steers Clear Of Agency’s OTC Authority, DSHEA, AER Law

This article was originally published in The Tan Sheet

Executive Summary

The FDA reauthorization bill Congress has passed does not rock the boat on FDA's current authority over either over-the-counter switches or dietary supplements

You may also be interested in...

FDA publishes food registry guidance

The agency solicits public comment on a draft guidance regarding the reportable food registry, which is slated for implementation Sept. 8. Under RFR, responsible parties - including manufacturers, processors and packagers - will need to alert the agency through its main Web portal that an adulterated food product has the potential to "cause serious adverse health consequences or death to humans," FDA said June 11. The comment period ends June 26. The guidance includes information on when RFR reports must be filed and the information they must include. As specified in the FDA Amendments Act of 2007, RFR reporting requirements exclude infant formula and dietary supplements (1"The Tan Sheet" Sept. 24, 2007)

Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access

FDA executives say behind-the-counter status for nonprescription drugs resonates in discussions at the agency, but a former deputy commissioner says the agency's BTC interests are stifled by not having explicit authority

Woodcock Stays At CDER: Drug Center’s Gain Is FDA Science Program’s Loss

Janet Woodcock's move to become director of the Center for Drug Evaluation and Research illustrates the operational challenges FDA faces: The agency remains committed to its historic bargain with the drug industry to take user fees in order to improve application review, but it is finding it increasingly hard to meet deadlines or to perform any other outside projects

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts